Dosing underway in Phase 1 clinical trial for ABD-147 (DLL3-targeting radiopharmaceutical) in patients with extensive stage small cell lung cancer and large cell neuroendocrine carcinoma of the lung; ...

Less than three years ago, a group of Canadian scientists got together to brainstorm a better radiopharmaceutical. Radiation has a long history in cancer care, used in imaging to detect the disease as ...

Lori Lyons-Williams has always been drawn to working in oncology. For the former Allergan leader and Neumora president, there are few opportunities more impactful than treating cancer—and ...

The US Food and Drug Administration (FDA) has granted clearance for Abdera Therapeutics' investigational new drug (IND) application to commence a Phase I clinical trial of ABD-147 for small cell lung ...

Company: Abdera Therapeutics Title: President & CEO Industry: Pharmaceuticals Notable in 2024: Lyons-Williams advanced Abdera's precision lung cancer therapies to the human trial phase and developed ...

Abdera Therapeutics has reported initial data from its Phase Ia study of the radiopharmaceutical biologic therapy, ABD-147, in treating individuals with small cell lung cancer (SCLC) and large cell ...

Abdera Therapeutics Inc., a Vancouver biopharma startup specializing in the treatment of cancer with radioisotopes, has landed $142 million in Series A and B financing, just a couple of years after ...

MENLO PARK, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and ...

Abdera Therapeutics Inc., a Vancouver biopharma startup specializing in the treatment of cancer with radioisotopes, has landed $142 million in Series A and B financing, just a couple of years after ...

Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today ...